RE: Deliverance28 Mar 2021 15:56
https://biontech.de/sites/default/files/2019-08/20180816_BioNTech-Signs-Collaboration-Agreement-with-Pfizer.pdf
I wonder if this will effect the Pfizer/Biontech deal for influenza.
Going back to Scancell, influenza also has its constant regions.
https://www.sciencemag.org/news/2020/12/innovative-universal-flu-vaccine-shows-promises-it-first-clinical-test
"HA’s bottom portion, or stalk, is less apt to vary, and epidemiological studies have shown people who have been exposed to an influenza strain and developed antibodies to the stalk can ward off a wide variety of other strains. So, the new universal flu vaccine candidate, one of a handful in development, puts HA’s stalk front and center. The study shows for the first time that “you can develop a vaccine strategy that produces stalk-reactive antibodies in humans,” says virologist Florian Krammer of the Icahn School of Medicine at Mount Sinai, who co-leads a multi-institutional universal flu vaccines consortium funded by the U.S. National Institute of Allergy and Infectious Diseases and helped develop the candidate tested in the new trial. Other clinical trials testing stalk-based universal flu vaccine candidates have yet to report data."
T Cells epitopes on the influenza stalk region may be good targets for an Immunobody vaccine.
So, if Covidity shows success, this may open the floodgates to treating influenza and perhaps many more viruses.